Skip to main content

Lexeo Therapeutics, Inc.

corporate_fare Company Profile

Lexeo Therapeutics, Inc.

LXEO·NASDAQ·Life Sciences·CIK 0001907108

We are a clinical stage genetic medicine company focused on cardiovascular diseases. We develop therapeutic candidates targeting the genetic causes of conditions such as Friedreich ataxia (FA) cardiomyopathy and plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy. Our lead cardiovascular product candidate, LX2006, treats FA cardiomyopathy and is in the SUNRISE-FA Phase 1/2 clinical trial and a Cornell investigator-initiated trial. In October 2025, we reported positive interim clinical data showing an encouraging safety profile and evidence of cardiac and functional benefit. Interim data presented in March 2026 at the American College of Cardiology (ACC) Annual Meeting showed sustained or deepening improvements in cardiac and neurologic measures of FA. In February 2026, we submitted the final registrational trial design and statistical analysis plan for the SUNRISE-FA 2 study to the U.S. Food and Drug Administration (FDA) and expect feedback in the second quarter of 2026, with plans to initiate a registrational study in the first half of 2026. Our second most advanced cardiovascular product candidate, LX2020, targets arrhythmogenic cardiomyopathy (ACM) caused by PKP2 gene mutations (PKP2-ACM). LX2020 is in the HEROIC-PKP2 Phase 1/2 clinical trial. In January 2026, we announced positive interim data from the HEROIC trial, where LX2020 was generally well tolerated, led to robust transduction, increased PKP2 protein expression, and clinically meaningful improvement or stabilization in arrhythmia burden for most participants. We plan to share additional safety and clinical efficacy data for LX2020 in the fourth quarter of 2026, after all high-dose participants complete at least twelve months of follow-up.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for LXEO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for LXEO spans 10-Q, 8-K.

Recent high-impact activity:

  • Lexeo 10-Q: $219.1M Cash Funds Operations Into 2028; Q3 Net Loss $38.3M
  • Lexeo's LX2020 Cuts NSVT 80%; FDA Open to NSVT Endpoint for Accelerated Approval
  • LX2020 Cuts Arrhythmia Burden 80% in High-Dose Cohorts; FDA Open to NSVT Endpoint
  • LX2006 Shows Sustained Neurologic Benefit Versus Natural-History Control
  • Lexeo Acquires Mantle Therapeutics for $8.3M Upfront, Adds Four FA Programs and Three CNS Collaborations

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$99.96M
Diluted EPS
-$1.86
Op. Cash Flow
-$98.56M
Free Cash Flow
-$98.96M
Operating Income
-$109.26M
Cash & Equivalents
$63M
Debt / Equity
0.00×
Shares Outstanding
73M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-132085

Short Interest & Short Volume

12.73 days to cover

FINRA reported short interest of 17,037,063 shares in LXEO as of the October 30, 2026 settlement, a 2.9% decrease from the prior period — about 12.7 days to cover at its recent average daily volume. On November 20, 2026, 48.6% of LXEO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,037,063 shares as of October 30, 2026
Change vs prior period▼ 2.9%
Days to cover12.73 at avg daily volume of 1,338,371
Daily short volume (FINRA facilities)48.6% of 594,603 shares on November 20, 2026
5-day average short volume47.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for LXEO, detected from its recent SEC filings.

ATM program1 shelf registration

New $300M Universal Shelf Filed · $116.6M Carried Forward, $183.4M New

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →
$2.9 -2.01% today
52-week range · as of 2026-11-16 $2.55 – $10.99
Market cap
$245.05M
Volume
1.8M (0.7× avg)
3-mo avg 2.6M
Live data · 2026-11-21 08:12 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LXEO - Latest Insights

LXEO
Nov 16, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.20
Real-time Price: $2.90 info
Change: -$0.2996 (-9%) info
Market Cap: $245.054M info
LXEO
Nov 16, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $2.90 info
Change: -$0.0896 (-3%) info
Market Cap: $245.054M info
LXEO
Nov 16, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $2.90 info
Change: +$0.0504 (+2%) info
Market Cap: $245.054M info
LXEO
Nov 02, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.14
Real-time Price: $2.90 info
Change: -$0.2396 (-8%) info
Market Cap: $245.054M info
LXEO
Sep 22, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $2.90 info
Change: -$0.9436 (-25%) info
Market Cap: $245.054M info
LXEO
Sep 22, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.90 info
Change: -$1.28 (-31%) info
Market Cap: $245.054M info
LXEO
Aug 12, 2026, 7:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $2.90 info
Change: -$1.89 (-39%) info
Market Cap: $245.054M info
LXEO
Aug 12, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.65
Real-time Price: $2.90 info
Change: -$1.75 (-38%) info
Market Cap: $245.054M info
LXEO
Aug 05, 2026, 8:19 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $2.90 info
Change: -$1.80 (-38%) info
Market Cap: $245.054M info
LXEO
Jun 15, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.75
Real-time Price: $2.90 info
Change: -$1.85 (-39%) info
Market Cap: $245.054M info
LXEO
May 11, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.83
Real-time Price: $2.90 info
Change: -$2.93 (-50%) info
Market Cap: $245.054M info
LXEO
May 11, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.83
Real-time Price: $2.90 info
Change: -$2.93 (-50%) info
Market Cap: $245.054M info
LXEO
Apr 30, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.69
Real-time Price: $2.90 info
Change: -$2.79 (-49%) info
Market Cap: $245.054M info
LXEO
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.90 info
Change: -$2.37 (-45%) info
Market Cap: $245.054M info
LXEO
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.90 info
Change: -$2.37 (-45%) info
Market Cap: $245.054M info
LXEO
Jan 12, 2026, 11:45 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.88
Real-time Price: $2.90 info
Change: -$4.98 (-63%) info
Market Cap: $245.054M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets